Table 2.
Primary outcomes and associated clinical variables of interest. Items in bold have P value <0.05
| Survival of Code (n = 105) | Died at Code (n = 71) | P-Value | Survival to Discharge (n = 38) | Died before Discharge (n = 139) | P-value | |
|---|---|---|---|---|---|---|
| Age (mean ± SD) | 60.2 ± 14.5 | 61.2 ± 15.4 | 0.65 | 60.3 ± 15.8 | 60.7 ± 14.6 | 0.87 |
| Female Sex | 31 (29.5%) | 22 (31.0%) | 0.87 | 8 (21.1%) | 45 (32.6%) | 0.23 |
| Coronary Artery Disease (CAD) | 30 (28.6%) | 22 (31.0%) | 0.74 | 16 (42.1%) | 36 (26.1%) | 0.07 |
| Cardiac implantable electronic device | 6 (8.5%) | 12 (11.4%) | 0.62 | 5 (13.2%) | 13 (9.4%) | 0.55 |
| Obesity | 36 (34.3%) | 14 (20.0%) | 0.04 | 13 (34.2%) | 37 (27.7%) | 0.42 |
| Monitored Unit (n = 146) | 74 (88.1%) | 56 (90.3%) | 0.79 | 26 (92.9%) | 104 (88.1%) | 0.74 |
| Witnessed | 95 (90.5%) | 61 (85.9%) | 0.47 | 38 (100%) | 118 (85.5%) | 0.008 |
| Heart Failure | 26 (24.8%) | 21 (30.0%) | 0.49 | 11 (28.9%) | 36 (26.1%) | 0.84 |
| Beta Blocker | 17 (23.9%) | 29 (27.6%) | 0.61 | 37 (26.8%) | 9 (23.7%) | 0.84 |
| Calcium Channel Blocker | 5 (7.0%) | 5 (4.8%) | 0.53 | 9 (6.5%) | 1 (2.6%) | 0.69 |
| Antiarrhythmic Drug | 11 (15.5%) | 18 (17.1%) | 0.84 | 24 (17.4%) | 5 (13.2%) | 0.63 |
| Renal Disease | 18 (17.1%) | 14 (19.7%) | 0.69 | 6 (15.8%) | 26 (18.8%) | 0.81 |
| Lung Disease | 38 (36.2%) | 18 (25.4%) | 0.14 | 13 (34.2%) | 43 (31.2%) | 0.70 |
| Respiratory arrest |
41 (39.0%) |
13 (18.3%) |
0.01 |
19 (50.0%) |
35 (25.2%) |
0.005 |
| Causes |
0.001 |
<0.0001 |
||||
| Acidemia | 5 (4.7%) | 1 (1.4%) | 0 (0%) | 6 (4.3%) | ||
| Cardiac tamponade | 2 (1.9%) | 5 (7.0%) | 0 (0%) | 7 (5.0%) | ||
| Electrolyte abnormality | 4 (3.6%) | 2 (2.8%) | 0 (0%) | 6 (4.3%) | ||
| Respiratory | 41 (39.0%) | 13 (18.3%) | 19 (50.0%) | 35 (25.2%) | ||
| Myocardial infarction | 6 (5.5%) | 5 (7.0%) | 3 (7.9%) | 8 (5.7%) | ||
| Pulmonary embolus | 3 (2.7%) | 6 (8.5%) | 1 (2.6%) | 8 (5.7%) | ||
| Shock | 19 (17.3) | 25 (35.2%) | 2 (5.2%) | 42 (30.2%) | ||
| Other | 18 (16.4%) | 3 (4.2%) | 11 (28.9%) | 10 (7.2%) | ||
| Unknown | 10 (9.5%) | 5 (7.0%) | 2 (5.2%) | 13 (9.4%) | ||
| Brady-PEA | 44 (41.9%) | 22 (31.0%) | 0.16 | 22 (57.9%) | 44 (31.9%) | 0.0045 |
| Vasopressin | 17 (16.2%) | 22 (31.0%) | 0.25 | 5 (13.2%) | 34 (24.4%) | 0.18 |
| Epinephrine | 93 (88.6%) | 70 (98.5%) | 0.003 | 29 (76.3%) | 134 (96.4%) | <0.001 |
| Atropine | 17 (16.2%) | 16 (22.5%) | 0.33 | 4 (10.5%) | 29 (20.9%) | 0.23 |
| Sodium bicarbonate | 65 (61.9%) | 60 (84.5%) | 0.001 | 16 (42.1%) | 109 (78.4%) | <0.0001 |
| Intubated prior to code or within 15 min of onset | 76 (72.3%) | 55 (77.5%) | 0.49 | 26 (68.4%) | 105 (76.0%) | 0.40 |